Clin2
NCT05958875Possibly a fitRecruiting

Six-week medicine switch for schizophrenia after first treatment failure

Schizophrenia and Related DisordersEarly Treatment-Resistance

Treatments studied

Part of Mental health clinical trials.

This trial tests whether a more intensive medication approach for schizophrenia (or related conditions) helps people who didn’t improve on their first tried medicine. Participants will usually switch medicines and be compared against “treatment as usual.”

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
418 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You’re between 18 and 70 years old.
  • You can give written consent (a legal guardian can help sign if allowed where you live).
  • You are diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
  • Your current episode didn’t respond to your current medicine (treatment failure) and you and your clinician plan to change the medicine.
  • You have enough symptoms and daily-life problems to meet the study’s minimum thresholds.
  • If you can get pregnant, you must use effective birth control and have a negative pregnancy test before randomization.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05603104Recruiting· Phase 3
Medication intensification after first treatment failure in mood and psychosis

This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.

Ramat Gan
NCT05973786Recruiting· Phase 3
Six-week medicine boost for bipolar depression after first treatment fails

This trial tests whether a stronger, more active medication plan for six weeks helps people with bipolar depression who did not improve with their first prescribed treatment. It compares the intensified medication plan to usual care to see which approach works better.

Innsbruck
NCT05973851Recruiting· Phase 3
Six-week medicine boost for depression after first treatment failure

This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.

Innsbruck
NCT06923891Not yet recruiting· Phase 4
Testing a new pill for early schizophrenia

This trial tests a new combination pill (xanomeline/trospium) for people who started treatment for schizophrenia in the last 5 years, to see if it helps better than their current medicine. You would stop your current antipsychotic and switch to this study drug under close doctor supervision.

Richmond, Texas
NCT07616999Recruiting
Long-term follow-up study of early psychosis treatment

This study follows people who were part of an earlier research trial about medication management during their first psychotic episode. Researchers want to understand how those early treatment choices affected their recovery over the past 20 years.

Hong Kong
NCT06924255Not yet recruiting· Phase 4
Switching antipsychotics to xanomeline/trospium for schizophrenia

This study tests how well people with schizophrenia can switch from their current antipsychotic medication to a new combination drug, xanomeline/trospium, either quickly or slowly over 8 weeks. It may be an option if your current medication causes side effects or is not working well enough.

Bellflower, California

Hear when a new Schizophrenia and Related Disorders trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.